Twist Bioscience Reports Second Quarter Fiscal 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Twist Bioscience Corporation (TWST) Misses Q2 EPS by 1c, Revenues Beat; Raises FY21 Revenues Guidance Above Consensus
May 6, 2021 5:15 PM EDTTwist Bioscience Corporation (NASDAQ: TWST) reported Q2 EPS of ($0.78), $0.01 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $31.2 million versus the consensus estimate of $28.32 million.
FISCAL 2021 SECOND QUARTER FINANCIAL RESULTS
Orders: Total orders received for the second quarter of fiscal 2021 were $41.7 million, compared to $24.6 million for the same period of fiscal 2020.Revenue: Total revenues were $31.2 million for the second quarter of fiscal 2021 compared to $19.3 million for the same period of fiscal 2020.Cost of Revenues: Cost of revenues for the second quarter of fiscal 2021 was $19.0 million... More